MK-677 vs Ipamorelin: Oral vs Injectable GH Support

Both MK-677 and Ipamorelin are ghrelin mimetics — they bind the GHS-R1a receptor, trigger GH release from the pituitary, and raise IGF-1. If you're comparing them at the level of mechanism, they look similar. If you're comparing them at the level of living with them for a twelve-week cycle, they feel very different.

MK-677 is oral, once-daily, cheap, and comes with a side-effect profile that the strength community tends to underestimate. Ipamorelin is injectable, pulsatile, and substantially cleaner. Understanding the trade-offs — not just reciting mechanism — is how you make the right choice for a specific goal.

What each compound does

MK-677 (Ibutamoren) is not technically a peptide. It's a small non-peptide molecule that mimics the action of ghrelin at GHS-R1a. The oral route works because its structure is not degraded by the GI tract the way a peptide would be. MK-677 has a half-life of roughly 24 hours, which means a single daily dose produces an extended, relatively sustained elevation in GH and IGF-1 throughout the day.

A Phase 2 clinical trial by Murphy et al. (1998, Journal of Clinical Endocrinology & Metabolism) showed MK-677 at 25 mg/day increased mean GH by approximately 97% and IGF-1 by 52% in healthy elderly subjects over two weeks. The compound has been through multiple clinical trials — more clinical data exists for MK-677 than for almost any other research-chemical GH secretagogue currently used in the strength community.

Ipamorelin is a pentapeptide (five amino acids) that also binds GHS-R1a but was specifically engineered for selectivity. Where GHRP-2 and GHRP-6 activate multiple pathways beyond GH release (cortisol, prolactin, appetite), Ipamorelin was designed to trigger GH release with minimal off-target activity. The result is a cleaner GH pulse: larger cortisol and prolactin rises don't accompany the GH signal the way they do with older GHRPs.

Ipamorelin has a short half-life — roughly 2 hours — which means you get a GH pulse that peaks and returns to baseline, more closely mimicking the body's natural pulsatile GH secretion pattern.

How the pharmacokinetics differ

This is the core practical difference. Natural GH release is pulsatile: several sharp peaks throughout the day, with the largest pulse occurring in deep sleep. MK-677's sustained action doesn't mimic that pattern — it produces a prolonged elevation that keeps GH and IGF-1 above baseline throughout the 24-hour window.

Ipamorelin, dosed two or three times daily, produces discrete pulses separated by return-to-baseline periods. When paired with CJC-1295 (no DAC) — a GHRH analogue that also has a short half-life — the two compounds produce a larger combined pulse that still follows a pulsatile pattern.

Whether pulsatile versus sustained GH elevation matters clinically is genuinely uncertain. Some endocrinologists argue that the pulsatile pattern is important for receptor sensitivity and long-term pituitary health. Others note that GH replacement therapy uses sustained daily dosing without obvious downregulation issues. The evidence is not decisive either way, but the argument for mimicking the natural pulsatile pattern is mechanistically coherent.

The side-effect profile: where MK-677 underdelivers

MK-677's side effects are real and often underweighted when people compare it to injectables on the basis of convenience:

Appetite. MK-677 produces a pronounced, persistent increase in appetite — not a 20-minute spike like GHRP-6, but a sustained baseline elevation in hunger that runs throughout the day. In a caloric surplus or maintenance phase this may be manageable or even welcome. In a cutting protocol where you're already fighting hunger, it is a serious liability.

Water retention. MK-677 consistently produces noticeable water retention, more than injectable GH secretagogues. This is partly GH-mediated and partly a direct effect of IGF-1 elevation on sodium and water handling. Users report 2–5 lb of scale weight increase in the first weeks that is not lean mass. For athletes who need to make a weight class or track body composition accurately, this is a problem.

Insulin sensitivity. Multiple clinical trials show MK-677 worsens insulin sensitivity at commonly used doses. The Murphy 1998 trial showed fasting glucose increased by 0.3–0.4 mmol/L and fasting insulin elevated significantly in treated subjects. For most young healthy users this is tolerable, but for anyone with impaired glucose metabolism or running MK-677 long-term it is a meaningful risk to monitor.

Lethargy. Many users report fatigue and cognitive fog, especially early in a protocol. This is partly a side effect of the appetite increase disrupting sleep patterns and partly a direct GH-related effect.

Ipamorelin's side-effect profile is substantially cleaner. The primary downsides are the requirement for injections (a practical barrier, not a pharmacological one) and the need for multiple daily doses (two or three) to achieve the GH elevation that one MK-677 pill delivers.

The cost and convenience calculation

MK-677 wins on convenience by a wide margin. One oral dose per day, no syringes, no reconstitution math, no injection-site management. Per-day cost is typically lower than Ipamorelin. For someone who is needle-averse or trying to keep a protocol simple, MK-677 is genuinely easier.

The convenience premium, though, is paid in side effects. If you run a 12-week MK-677 cycle and the water retention and appetite make the protocol miserable — or the insulin sensitivity worsening requires active management — the convenience advantage narrows.

Ipamorelin with CJC-1295 (no DAC) requires subcutaneous injections, but insulin syringe injections are small, low-pain, and straightforward once you've done it a few times. Reconstitution is a 5-minute task. If the cleaner side-effect profile materially improves your experience over 12 weeks, the practical cost is worth it.

For a full protocol guide on the Ipamorelin plus CJC-1295 stack, see Ipamorelin protocol. For MK-677 specifically versus injectable options, see MK-677 vs injectable GH secretagogues.

Who should choose which

MK-677 makes more sense if:

• You are in a gaining phase where appetite increase is useful
• You are needle-averse and the injection barrier is real
• You want the most clinical trial data behind your compound
• Cost is a significant constraint

Ipamorelin makes more sense if:

• You are in a cutting phase and can't afford amplified appetite
• You want the cleanest possible GH signal with minimal cortisol and prolactin effects
• You are stacking with CJC-1295 for a combined pulsatile GHRH + ghrelin mimetic protocol
• You have any reason to be cautious about insulin sensitivity

Neither is appropriate if:

• Your primary goal is direct anabolic effects (neither produces a meaningful anabolic response in the absence of adequate protein and training)
• You expect significant body composition change on peptides alone
• You haven't addressed the basics: sleep, training, nutrition, recovery

The pulsatile question

There's an argument in some circles that sustained GH elevation (as with MK-677) downregulates the GH axis more than pulsatile dosing does, potentially leading to greater blunting of the body's own GH production. The mechanism is plausible: sustained receptor stimulation generally produces more receptor downregulation than intermittent pulsatile stimulation.

The evidence in humans is mixed. MK-677's clinical trials did not show dramatic reductions in endogenous GH pulsatility, though they also did not show maintenance of baseline pulsatility. The picture is complicated. Most users who run MK-677 for 12–24 weeks and stop report that GH axis function returns to subjective baseline within a few weeks — suggesting the downregulation is reversible.

The theoretical argument favors pulsatile dosing on mechanistic grounds. Whether that advantage is clinically meaningful in practice is unknown.

For the broader context on GH secretagogues, see the GH secretagogues guide and choosing between Sermorelin, Ipamorelin, and Tesamorelin.

Related reading

• GH secretagogues guide
• Ipamorelin protocol
• MK-677 vs injectable GH secretagogues
• Choosing between Sermorelin, Ipamorelin, and Tesamorelin
• Side effects overview